The role of RAS oncogene in lung cancer survival
Author Information
Author(s): Celine Mascaux, Nicolas Iannino, Bruno Martin, Marc Paesmans, Thierry Berghmans, Marie Dusart, Alain Haller, Philippe Lothaire, Anne-Pascale Meert, Sophie Noel, Jean-Jacques Lafitte, Jean-Paul Sculier
Primary Institution: Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
Hypothesis
What is the prognostic significance of RAS mutations in lung cancer survival?
Conclusion
RAS mutations are associated with worse survival in patients with non-small-cell lung cancer.
Supporting Evidence
- RAS mutations are detected in 15–20% of non-small-cell lung cancer cases.
- 29 studies were evaluable for meta-analysis, showing a combined hazard ratio of 1.35.
- Studies using PCR showed a worse survival impact compared to those using immunohistochemistry.
Takeaway
This study found that changes in a gene called RAS can make lung cancer patients live shorter lives. It's like finding out that a broken toy doesn't work well and can break even more.
Methodology
A systematic review and meta-analysis of 53 studies assessing the prognostic value of RAS mutations or p21 overexpression on survival in lung cancer.
Potential Biases
Potential bias due to the exclusion of non-English studies and reliance on published data.
Limitations
The study is based on retrospective data and may be affected by publication bias.
Participant Demographics
Patients with lung cancer, including those with non-small-cell lung cancer and adenocarcinoma.
Statistical Information
P-Value
1.35
Confidence Interval
95% CI: 1.16–1.56
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website